Versana Premier; Versana Premier Lotus; LOGIQ F

The Versana Premier, Versana Premier Lotus, and LOGIQ F are general-purpose diagnostic ultrasound systems designed for imaging, measurement, display, and analysis across numerous clinical applications. These systems operate using various imaging modes and have demonstrated safety and effectiveness through comprehensive non-clinical testing, affirming substantial equivalence to predicate devices.

GE Medical Systems Ultrasound and Primary Care Diagnostics, LLC's Versana Premier, Versana Premier Lotus, and LOGIQ F diagnostic ultrasound systems have successfully completed a regulatory review, establishing their substantial equivalence to previously marketed medical devices. This clearance permits their market release, while also confirming that the devices remain subject to standard regulatory controls including requirements for registration, listing, good manufacturing practices, and accurate labeling. The Versana Premier, Versana Premier Lotus, and LOGIQ F are general-purpose diagnostic ultrasound systems intended for use by trained healthcare professionals for imaging, measurement, display, and analysis across various clinical applications such as fetal/obstetrics, abdominal, cardiac, vascular, and interventional guidance. Operating in B, M, and Doppler imaging modes within hospital or medical clinic environments, these systems underwent comprehensive non-clinical testing for acoustic output, biocompatibility, and safety, confirming adherence to applicable medical device safety standards. The manufacturer asserts the systems are safe, effective, and perform in a manner substantially equivalent to their predicate devices.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific technological advancements or new features do the Versana Premier, Versana Premier Lotus, and LOGIQ F systems offer compared to their predicate devices, beyond general capabilities?; Can the non-clinical testing results, particularly regarding acoustic output and biocompatibility, be quantified or detailed further to understand the specific safety margins achieved?; Are there any particular clinical scenarios or patient populations for which these new systems offer superior diagnostic performance or workflow improvements?; What post-market surveillance strategies are in place to monitor the long-term safety and effectiveness of these devices once widely deployed in clinical settings?; How do the 'Lotus' features of the Versana Premier Lotus specifically enhance diagnostic capabilities or user experience beyond the standard Versana Premier model?